Skip to content

Mannkind MNKD Liability Sale Of Future Royalties Non Current

Liability Sale Of Future Royalties Non Current at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.02B+9.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$305.04M+22.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$3.28M-25.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Geron logo
GeronGERN
$110.38M0.0%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.21B+6.0%
Enterprise value$1.17B+5.5%
P/E233.9×
P/S3.4×-0.5×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept mnkd:LiabilitySaleOfFutureRoyaltiesNonCurrent.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's liability sale of future royalties non current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's liability sale of future royalties non current?
Mannkind (MNKD) reported liability sale of future royalties non current of $136.56M in Q1 2026.
How has Mannkind's liability sale of future royalties non current changed year-over-year?
Mannkind's liability sale of future royalties non current decreased by 0.6% year-over-year, from $137.42M to $136.56M.
What is the long-term trend for Mannkind's liability sale of future royalties non current?
Over 2 years (2023 to 2025), Mannkind's liability sale of future royalties non current has grown at a 0.3% compound annual growth rate (CAGR), from $136.05M to $136.99M.
What does liability sale of future royalties non current mean?
This represents the long-term portion of obligations resulting from the monetization of future royalty rights. It indicates the total amount of future revenue streams that have been pre-sold to investors to secure long-term funding. This metric is essential for understanding the long-term impact of royalty-based financing on future profitability.